REMARKS

The title and abstract have been amended to more clearly reflect applicant's invention of a method of treatment.

Claims 1-11 have been amended to put them in appropriate U.S. method-of-treatment format. The method of treatment language appears in the specification at page 2, lines 19-22.

Claim 12 has been canceled herein without prejudice to the prosecution thereof in a continuing application.

New claims 13-23 are directed to a method of decreasing body weight and correspond in scope to the methods of claims 1-11. Activity of the reversible selective inhibitors of MAO-A, the reversible selective inhibitors of MAO-B and the reversible mixed inhibitors of MAO-A and MAO-B in decreasing body weight is found in the specification at page 2, lines 10-13.

Claims 1-11 and 13-23 are in the application as amended.

Attached hereto is a marked-up version of the changes made to the claims by the instant amendment. The marked-up version is entitled "Version With Markings To Show Changes Made".

10069179.021502

Respectfully submitted,

Date: 2/15/02

Paul E. Dupont
Reg. No. 27,438

Address
Patent Department
Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Telephone No. (610) 889-8802
Facsimile: (610) 889-8799

Version With Markings to Show Changes Made

In the specification:

The title has been amended as follows:

USE OF MONOAMINE OXIDASE INHIBITORS [FOR THE MANUFACTURE OF DRUGS INTENDED] FOR THE TREATMENT OF OBESITY

The abstract page has been amended as follows:

[USE OF MONOAMINE OXIDASE INHIBITORS FOR THE MANUFACTURE OF DRUGS INTENDED FOR THE TREATMENT OF OBESITY]

[SANOFI-SYNTHELABO]

[ABSTRACT:] **ABSTRACT**

The present invention relates to the use of reversible selective inhibitors of monoamine oxidase A (MAO-A), reversible selective inhibitors of monamine oxidase B (MAO-B) or reversible mixed inhibitors of MAO-A and MAO-B [in the manufacture of drugs intended] for the treatment of obesity.

In the Claims:

Claims 1-11 have been amended as follows:

1. (Amended) [Use of] A method for the treatment of obesity which comprises administering to a patient in need of such treatment a reversible selective inhibitor of monoamine oxidase A, a reversible selective inhibitor of monoamine oxidase B or a reversible mixed inhibitor of monoamine oxidase A and B [for the manufacture of drugs intended for the treatment of obesity].

2. (Amended) [Use of] A method according to claim 1 which comprises administering a reversible mixed inhibitor of monoamine oxidase A and B [according to claim 1].

3. (Amended) ~~The use~~ A method according to claim 2 wherein the reversible mixed inhibitor of monoamine oxidase A and B is chosen ~~among~~ from [3(*S*),3a(*S*)]-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1*H*-oxazolo[3,4-a]quinolin-1-one, (*R*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)benzofuran-3-yl]oxazolidin-2-one and (*R*)-5-(methoxymethyl-3-(6-cyclopropyl-methoxybenzofuran-3-yl)oxazolidin-2-one.

4. (Amended) [Use of] A method according to claim 1 which comprises administering a reversible selective inhibitor of monoamine oxidase B [according to claim 1].

5. (Amended) [The use] A method according to claim 4 wherein the reversible selective inhibitor of monoamine oxidase B is chosen among lazabemide, milacemide, caroxazone and IFO.

6. (Amended) ~~The use~~ A method according to claim 4 wherein the reversible selective inhibitor of monoamine oxidase B is (*S*)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]oxazolidin-2-one.

7. (Amended) [Use of] A method according to claim 1 which comprises administering a reversible selective inhibitor of monoamine oxidase A [according to claim 1].

8. (Amended) [The use] A method according to claim 7 wherein the reversible selective inhibitor of monoamine oxidase A is chosen [among] from befloxatone, moclobemide, brofaromine, phenoxathine, esuprone, befol, RS 8359 [(Sankyo)], T794 [(Tanabe)], KP9 [(Krenitsky, USA)], E 2011 [(Eisei)], toloxatone, pirlindole, amiflamine, sercloremine and bazinaprine.

9. (Amended) [The use] <u>A method</u> according to claim [7] <u>8</u> wherein the reversible selective inhibitor of monoamine oxidase A is befloxatone.

10. (Amended) [The use] <u>A method</u> according to claim 9 wherein the dosage amount of befloxatone is from about 2.5 to 40 mg per day.

11. (Amended) [The use] <u>A method</u> according to claim 10 wherein the amount of befloxatome [to be administered] is from <u>about</u> 10 to 20 mg.

Claim 12 has been canceled.

Claims 13-23 have been added.

10069179.021502